These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11578586)

  • 21. [New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
    Corbaux P; Sabatier R
    Bull Cancer; 2020 Oct; 107(10):959-960. PubMed ID: 32977934
    [No Abstract]   [Full Text] [Related]  

  • 22. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
    Ghebeh H; Mohammed S; Al-Omair A; Qattan A; Lehe C; Al-Qudaihi G; Elkum N; Alshabanah M; Bin Amer S; Tulbah A; Ajarim D; Al-Tweigeri T; Dermime S
    Neoplasia; 2006 Mar; 8(3):190-8. PubMed ID: 16611412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
    Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
    Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
    [No Abstract]   [Full Text] [Related]  

  • 24. [CD44v6 expression in er-negative and PgR-negative infiltrating ductal breast carcinomas].
    Ruibal A; del Río MC; Arias JI
    Med Clin (Barc); 2005 Oct; 125(12):475-6. PubMed ID: 16216206
    [No Abstract]   [Full Text] [Related]  

  • 25. Study of the expression on the CD44v5 adhesion molecule in invasive lobular carcinomas of the breast. Association between negativity and cellular S-phase fraction >7%.
    Ruibal A; Arias J; Del Rio MC; Schneider J; Tejerina A
    Int J Biol Markers; 2000; 15(2):195-6. PubMed ID: 10883896
    [No Abstract]   [Full Text] [Related]  

  • 26. Metaplastic carcinoma of the breast: analysis of eight Asian patients with special emphasis on two unusual cases presenting with inflammatory-type breast cancer.
    Kuo SH; Chen CL; Huang CS; Cheng AL
    Anticancer Res; 2000; 20(3B):2219-22. PubMed ID: 10928181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 28. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence.
    Coradini D; Pellizzaro C; Veneroni S; Ventura L; Daidone MG
    Br J Cancer; 2002 Nov; 87(10):1105-11. PubMed ID: 12402149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steroid receptor heterogeneity in relation to DNA index in breast cancer: a multiparameter flow cytometric approach on paraffin-embedded tumor samples.
    Leers MP; Nap M
    Breast J; 2001; 7(4):249-59. PubMed ID: 11678803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic targeting in breast cancer].
    Penault-Llorca F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical-biological differences between invasive ductal carcinomas and breast lobular carcinomas. Preliminary results].
    Ruibal A; Núñez MI; del Río Mf; Arias J; Martínez MI; Rabadán J; Tejerina A
    Rev Esp Med Nucl; 1999; 18(2):84-7. PubMed ID: 10352319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytosolic tissue-type plasminogen activator (t-PA) levels in breast tumors and hormone dependence. Role of pS2.
    Ruibal A; Alvarez A; Fernández Llana B; Fernández Fernández M; Roiz MC; Allende MT
    Int J Biol Markers; 1994; 9(4):251-3. PubMed ID: 7836805
    [No Abstract]   [Full Text] [Related]  

  • 33. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J; Gebhard S; Gomez F
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen and progesterone receptors in breast cancer.
    Couch P
    Am J Dermatopathol; 1997 Oct; 19(5):553-5. PubMed ID: 9335253
    [No Abstract]   [Full Text] [Related]  

  • 36. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
    Yie SM; Luo B; Ye NY; Xie K; Ye SR
    Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of oestrogen receptor-beta in invasive breast tumours].
    Péter I; Számel I; Péley G
    Magy Onkol; 2004; 48(1):63-9. PubMed ID: 15105898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flow cytometric steroid receptor analysis.
    Schutte B; Scheres HM; De Goeij AF; Rousch MJ; Blijham GH; Bosman FT; Ramaekers FC
    Prog Histochem Cytochem; 1992; 26(1-4):68-76. PubMed ID: 1484969
    [No Abstract]   [Full Text] [Related]  

  • 40. A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas.
    Soslow RA; Carlson DL; Horenstein MG; Osborne MP
    Breast Cancer Res Treat; 2000 May; 61(2):161-70. PubMed ID: 10942102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.